• All posts
  • Alzheimer's
  • ANVISA
  • Author: Allan Matsui
  • Author: Jairo Utimi
  • Author: Claudia Cilento
  • Author: Nilva Bortoleto
  • BPF
  • Cannabidiol
  • Cancer
  • Cannabis
  • Coronavirus
  • Covid-19
  • challenges
  • Epilepsy
  • pharmaceutical
  • IFA
  • pharmaceutical industry
  • Inovatie
  • medicines
  • opportunities
  • Parkinson
  • pharmaceuticals
  • pharmaceutical industry
  • Author: Camille Rodrigues da Silva
  • Incremental innovation
  • Investments
  • Marketing
  • News
  • Incremental innovation
  • Good Manufacturing Practices
Search
ANVISA – Post-pandemic challenges and perspectives.
  • Apr 7

ANVISA – Post-pandemic challenges and perspectives.

What is the purpose of registration submission guide, based on data from scientific literature?
  • Apr 7

What is the purpose of registration submission guide, based on data from scientific literature?

Clinical research in Brazil – New horizons, new challenges
  • Dec 22, 2021

Clinical research in Brazil – New horizons, new challenges

ANVISA has just published the new version of the Cadifa Manual, but what were the main changes?
  • Dec 22, 2021

ANVISA has just published the new version of the Cadifa Manual, but what were the main changes?

Unraveling the Abbreviated Development Path
  • Feb 9, 2021

Unraveling the Abbreviated Development Path

Publication of the Public Consultation for the review of RDC 200 - what is new?
  • Feb 9, 2021

Publication of the Public Consultation for the review of RDC 200 - what is new?

NEW REGULATORY FRAMEWORK OF API
  • Feb 9, 2021

NEW REGULATORY FRAMEWORK OF API

INCREMENTAL INNOVATION: How to prepare for the changes that will come with the revision of RDC 200
  • Feb 9, 2021

INCREMENTAL INNOVATION: How to prepare for the changes that will come with the revision of RDC 200

COVID-19: What facilities is ANVISA providing at this time of crisis?
  • Feb 9, 2021

COVID-19: What facilities is ANVISA providing at this time of crisis?

Why are 24% of drug registrations still rejected?
  • Feb 9, 2021

Why are 24% of drug registrations still rejected?

Cannabis: challenges and opportunities
  • Feb 9, 2021

Cannabis: challenges and opportunities

NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
  • Feb 9, 2021

NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?

Publication of the new API regulatory framework: what is essential to know?
  • Feb 9, 2021

Publication of the new API regulatory framework: what is essential to know?

What is important about the new regulatory framework for good manufacturing practices?
  • Feb 9, 2021

What is important about the new regulatory framework for good manufacturing practices?

Cannabis for therapeutic uses: is this a new market?
  • Feb 9, 2021

Cannabis for therapeutic uses: is this a new market?

DDCM: what are the points that generate the most demands at ANVISA (Part 2)?
  • Feb 9, 2021

DDCM: what are the points that generate the most demands at ANVISA (Part 2)?

New rules for outsourcing in the pharmaceutical industry: many possibilities!
  • Feb 9, 2021

New rules for outsourcing in the pharmaceutical industry: many possibilities!

Barra-Books2.jpg
E-BOOKS
CONTEÚDOS EXCLUSIVOS PARA AUXILIAR EM
SEU TRABALHO
Acesse
Back-Receba.jpg
Receive our exclusive content

Thanks for sending!

CONTACT US
We call you
Florida Street, 1.758, 9th floor
Set 91, 04565-001
Brooklin, São Paulo/SP
HOME
About Us
Solutions
Customers
Events
Books
Contact
BLOG
CONTACT US
55 11 4810 6360
contato@inovatie.net.br
FIND US
Portuguese
English
Copyright 2020 - Inovatie Serviços em Saúde